Amid all the posters, plenaries, and presentations of the nation’s biggest neurology conference, one story stood out: Spinal muscular atrophy, once an untreatable condition, has become the staging ground for one of the drug industry’s most intense competitions.

This year’s American Academy of Neurology meeting offered plenty of answers about SMA treatments from Novartis (NVS), Roche (RHHBY), and Biogen (BIIB) — but left enough questions to stir debate over just which therapy will lead the SMA market in years to come.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy